Bio-Techne Corp Stock Forecast for 2023 - 2025 - 2030
Updated on 04/24/2024
Bio-Techne Corp Stock Forecast and Price Target
In recent months, two notable analysts have provided yearlong price targets for Bio-Techne Corp, with the average target coming in at $80.00. If it were to be achieved, this would result in a potential upside of approximately 25.94 percent from the most recent closing price in April, 2024. The high end is $95.00, and the low is $65.00. If you want to invest in TECH stock, you might also want to take a look at how its competitors are doing.
25.94% Upside
Bio-Techne Corp Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Bio-Techne Corp's Price has decreased from $55.53 to $0.00 – a 100.00% drop. The next year looks promising for Bio-Techne Corp, with analysts predicting Fair Value of $111.55 – an increase of 100.00%. Over the next seven years, experts anticipate that Bio-Techne Corp's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.80 | Buy/Sell | $178.42 | 12.63% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$273.01 | Buy/Sell | $303.65 | 16.20% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.08 | Buy/Sell | $87.82 | 19.26% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$201.99 | Buy/Sell | $299.62 | 41.10% |
Bio-Techne Corp Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Bio-Techne Corp's Revenue has grown, increasing from $738.69M to $1.14B – a growth of 53.88%. The next year looks promising for Bio-Techne Corp, with analysts predicting Revenue of $1.27B – an increase of 12.08%. Over the next seven years, experts anticipate that Bio-Techne Corp's Revenue will grow at a rate of 57.73%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$91.20 | Buy/Sell | $111.56 | 20.07% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$51.74 | Buy/Sell | $77.05 | 49.21% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
.jpg)
Bio-Techne Corp Dividend per Share Forecast for 2023 - 2025 - 2030
Bio-Techne Corp's Dividend per Share has decreased by 75.00% In the last three years, from $1.28 to $0.32. In the following year, the 3 analysts surveyed believe that Bio-Techne Corp's Dividend per Share will decrease by 0.00%, reaching $0.32. According to professionals, by 2030, Bio-Techne Corp's Dividend per Share will have decreased by 0.00%, falling down to $0.32.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$92.26 | Buy/Sell | $85.71 | 8.39% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.54 | Buy/Sell | $17.90 | 89.75% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$65.07 | Buy/Sell | $34.00 | 76.73% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$11.71 | Buy/Sell | $20.42 | 117.76% |
Bio-Techne Corp EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Bio-Techne Corp's EBITDA has grown by 72.89%, rising from $199.00M to $344.05M. For next year, analysts predict EBITDA of $511.33M, which would mean an increase of 48.62%. Over the next seven years, experts predict that Bio-Techne Corp's EBITDA will grow at a rate of 75.46%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$16.59 | Buy/Sell | $33.78 | 80.83% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$23.29 | Buy/Sell | $52.00 | 127.57% |
Bio-Techne Corp EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Bio-Techne Corp's EBIT has grown by 86.46%, rising from $150.76M to $281.11M. For next year, analysts predict EBIT of $474.55M, which would mean an increase of 68.81%. Over the next seven years, experts predict that Bio-Techne Corp's EBIT will grow at a rate of 174.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$37.02 | Buy/Sell | $63.29 | 108.00% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$46.11 | Buy/Sell | $42.58 | 19.28% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.43 | Buy/Sell | $9.94 | 117.73% |
Bio-Techne Corp EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Bio-Techne Corp's EPS has decreased from $1.14 to $0.00 – a 100.00% drop. The next year looks promising for Bio-Techne Corp, with analysts predicting EPS of $2.29 – an increase of 100.00%. Over the next seven years, experts anticipate that Bio-Techne Corp's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.42 | Buy/Sell | $25.00 | 114.54% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$31.67 | Buy/Sell | $40.00 | 37.35% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.46 | Buy/Sell | $6.00 | 23.84% |
.jpg)